Company: IXHL
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001213900-25-092837
Chunk: 316

Company: Incannex Healthcare Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1A
Chunk 316
---
 success depends on our ability to protect our intellectual
property and our proprietary technology, and we may not be able to protect our intellectual property rights throughout the world.

Our success is to a certain degree also dependent
on our ability to obtain and maintain protection of our intellectual property portfolio where applicable, to receive/maintain orphan drug
designation/status and resulting marketing exclusivity for our drug candidates, and we may not be able to protect our intellectual property
rights throughout the world.

We may be materially adversely affected by our
failure or inability to protect our intellectual property rights. Without the granting of these rights, the ability to pursue damages
for infringement would be limited. Similarly, any know-how that is proprietary or particular to our technologies may be subject to risk
of disclosure by employees or consultants despite having confidentiality agreements in place.

Any future success will depend in part on whether
we can obtain and maintain patents to protect our own products and technologies; obtain licenses to the patented technologies of third
parties; and operate without infringing on the proprietary rights of third parties. As noted above, we are currently exploring potential
patent protection strategies for our lead drug candidate, PSX-001. However, these efforts may be unsuccessful. Biotechnology patent matters
can involve complex legal and scientific questions, and it is impossible to predict the outcome of biotechnology and pharmaceutical patent
claims. Any of our future patent applications may not be approved, or we may not develop additional products or processes that are patentable.
Filing, prosecuting and defending patents on drug candidates in all countries throughout the world would be prohibitively expensive. In
addition, the laws of some international countries do not protect intellectual property rights to the same extent as federal or state
laws in the United States. For instance, some countries in which we may sell our drug candidate or license our intellectual property may
fail to protect our intellectual property rights to the same extent as the protection that may be afforded in the United States or Australia.
Some countries in Europe and China have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third
parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these
countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are, or any of
our licensors is, forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position
or commercial advantage may be impaired, and our